Antiviral agents

  • Jeffrey S. Berns
  • Alden Doyle
  • Nishaminy Kasbekar

The ability to prevent viral infections is becoming an increasingly important part of clinical medicine. The interest in the development of new antiviral agents and new uses of these medications is driven in large part by the treatment of human immunodeficiency virus (HIV) and growth of the field of transplantation. Although most of the use of these antiviral agents is well-tolerated by patients, there are a variety of potential kidney toxicities that should be appreciated. The most important of these toxicities is acute kidney injury (AKI), which is the main focus of this chapter. We will also consider fluid and electrolyte complications observed with these medications as well as other direct toxic effects on the kidneys. For information regarding clinical pharmacokinetics of antiviral agents and dosing guidelines for their use in patients with kidney injury, which are not discussed in detail here, the reader is referred to several recent reviews [1-5]. This discussion is limited to antiviral agents that are administered orally or parenterally only; topical and intraocular applications are not addressed. The nephrotoxicity of immunomodulatory agents that have anti-viral properties in vivo such as interferon alpha are discussed elsewhere.


Human Immunodeficiency Virus Acute Kidney Injury Lactic Acidosis Antiviral Agent Nucleoside Reverse Transcriptase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG: Antiviral therapy for HIV patients with renal insufficiency. JAIDS 1999; 21: 384-395.PubMedGoogle Scholar
  2. 2.
    Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM. Drug prescribing in renal failure. In: Dosing guidelines for adults, 4th edition. Philadelphia: American College of Physicians, 1999.Google Scholar
  3. 3.
    Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991; 1: 1061-1080.PubMedGoogle Scholar
  4. 4.
    Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of antiretroviral drugs in hemodialysis. Kidney Int 2001; 60: 821-830.PubMedGoogle Scholar
  5. 5.
    Berns JS, Kasbekar N. Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006;1:117-129.PubMedGoogle Scholar
  6. 6.
    Tucker WE. Preclinical toxicology profile of acyclovir: an overview. Am J Med 1982; 73: 27-30.PubMedGoogle Scholar
  7. 7.
    Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982; 73: 182-185.PubMedGoogle Scholar
  8. 8.
    Selby PJ, Powles RL, Jameson B, Kay HEM, Watson JG, Thornton R, Morgenstern G, Clink HM. Parenteral acyclovir therapy for herpes virus infections in man. Lancet 1979; 2: 1267-1270.PubMedGoogle Scholar
  9. 9.
    Keeney RE, Kirk LE, Brigden D. Acyclovir tolerance in humans. Am J Med 1982; 73: 171-181.Google Scholar
  10. 10.
    Bean B, Aeppli D. Adverse effects of high dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985; 151: 362-365.PubMedGoogle Scholar
  11. 11.
    Spiegal D, Lau K. Acute renal failure and coma secondary to acyclovir therapy. JAMA 1986; 255: 1882-1883.PubMedGoogle Scholar
  12. 12.
    Sawyer MH, Webb DF, Balow JE, Straus SE. Acyclovir induced renal failure: clinical course and histology. Am J Med 1988; 84: 1067-1071.PubMedGoogle Scholar
  13. 13.
    Giustina A, Romanelli G, Cimino A, Brunori G. Low dose acyclovir and acute renal failure. Ann Intern Med 1988; 108: 312.PubMedGoogle Scholar
  14. 14.
    Rashed A, Azadeh B, Abu-Romeh SH. Acyclovir-induced acute tubulo-interstitial nephritis. Nephron 1990; 56: 436-438.PubMedGoogle Scholar
  15. 15.
    Eck P, Silver SM, Clark EC. Acute renal failure and coma after a high dose of oral acyclovir. N Engl J Med 1991; 325: 1178-1179.PubMedGoogle Scholar
  16. 16.
    Bianchetti M, Roduit C, Oetliker OH. Acyclovir-induced renal failure: course and risk factors. Pediatr Nephrol 1991; 5: 238-239.PubMedGoogle Scholar
  17. 17.
    Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman A. Rapidly progressive acute renal failure due to acyclovir: Case report and review of the literature. Am J Kid Dis 1993; 22(4): 611-615.PubMedGoogle Scholar
  18. 18.
    Hsu CC, Lai TL, Lien WC, Chen WJ, Fang CC. Emergent hemodialysis for acyclovir toxicity.Am J Emerg Med, 2005; 23(7); 899-900.PubMedGoogle Scholar
  19. 19.
    Khajehdehi P, Jamal JA, Bastani B. Removal of acyclovir during veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. Clin Nephrol 2000; 54(4): 351-5.PubMedGoogle Scholar
  20. 20.
    Sodhi PK, Ratan SK. Case of chronic renal dysfunction following treatment with oral acyclovir. Scand J Infect Dis 2003; 35(10):770-2.PubMedGoogle Scholar
  21. 21.
    Potter JL, Krill CE. Acyclovir crystalluria. Pediatr Infect Dis 1986; 5: 710-712.PubMedCrossRefGoogle Scholar
  22. 22.
    DosSantos MDeFF, DosSantos OFP, Boim MA, Razvickas CV, DeMoura LAR, Ajzen H, Schor N. Nephrotoxicity of acyclovir and ganciclovir in rats: evaluation of glomerular hemodynamics. J Am Soc Nephrol 1997; 8: 361-367.Google Scholar
  23. 23.
    Yavuz BB, Cankurtaran M, Halil M, Dagli N, Kirkpantur A. Renal dysfunction after oral acyclovir in a geriatric woman: a case report. Scand J Infect Dis 2005; 37(8):611-613.PubMedGoogle Scholar
  24. 24.
    MacDiarmaid-Gordon AR, O’Connor M, Beaman M, Ackrill P. Neurotoxicity associated with oral acyclovir in patients undergoing dialysis. Nephron 1992; 62: 280-283.PubMedGoogle Scholar
  25. 25.
    lmond MK, Fan S, Dhillon S, Pollock AM, Raftery MJ. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing hemodialysis. Nephron 1995; 69: 428-432.Google Scholar
  26. 26.
    Catalano C, Conforto L. Valacyclovir-related neuro- and nephrotoxicity in two geriatric patients. G Ital Nefrol (Italian) 2005; Suppl 31: S132-4.Google Scholar
  27. 27.
    Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV ) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997; 76: 369-380.PubMedGoogle Scholar
  28. 28.
    Rivaud E, Massiani M-A, Vincent F, Azoulay E, Couderc L-J. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. Arch Int Med 2000; 160: 1705-1706.Google Scholar
  29. 29.
    Leaf AN, Laubenstein LJ, Raphael B, Hochster H, Baez L, Karpatkin S. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-1) infection. Ann Intern Med 1988; 109: 194-197.PubMedGoogle Scholar
  30. 30.
    Berns J. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura associated with HIV infection. In: Renal and Urologic Aspects of HIV Infection. Kimmel PL, Berns JS (editors). Churchill Livingstone, Inc., Philadelphia, PA 1995; p. 111-133.Google Scholar
  31. 31.
    Kuypers DR, Vandooren AK, Lerut E, Evenepoel P, Claes K, Snoeck R, Naesens L, Vanrenterghem Y. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005; 5:1997-2004.PubMedGoogle Scholar
  32. 32.
    Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006;8:76-85.PubMedGoogle Scholar
  33. 33.
    Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998; 44: 97-106.PubMedGoogle Scholar
  34. 34.
    Lalezari JF, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, Jaffe HS. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl] cytosine (Cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171: 788-796.Google Scholar
  35. 35.
    Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997: 126: 257-263.PubMedGoogle Scholar
  36. 36.
    Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PF, Falloon J, Davey RT Jr, Kovacs JA, Walker RE, Whitcup SM, Nussenblatt RB, Lane HC, Masur H. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viremia. Antimicrob Agents Chemother 1996; 39: 882-886.Google Scholar
  37. 37.
    Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kupperman BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS. Randomized, controlled trial of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J AIDS Hum Retrovirol 1998;17: 339-344.Google Scholar
  38. 38.
    Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir novel substrates for human and rat renal organic anion transporter 1. Mol Pharmcol 1999; 56: 570-580.Google Scholar
  39. 39.
    Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJM, Jaffe HS. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995; 39: 1247-1252.PubMedGoogle Scholar
  40. 40.
    Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Cidofovir, a new agent with potent anti-herpes virus activity. Antiviral Chem Chemother 1996; 7: 115-127.Google Scholar
  41. 41.
    Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11: 383-393.PubMedGoogle Scholar
  42. 42.
    Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, Ullmann J, Musso M, Trenschel R, Ribaud P, Bornhauser M, Cesaro S, Crooks B, Dekker A, Gratecos N, Klingebiel T, Tabliaferri E, Ullmann AJ, Wacker P, Cordonnier C. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 2001; 15: 388-392.Google Scholar
  43. 43.
    Kay TD, Hogan PG, McLeod SE, Johnson DW. Severe irreversible proximal renal tubular acidosis and azotaemia secondary to cidofovir. Nephron 2000; 86: 348-349.PubMedGoogle Scholar
  44. 44.
    Vandercam B, Moreau M, Goffin E, Marot JC, Cosyns JP, Jadoul M. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29: 948-949.PubMedGoogle Scholar
  45. 45.
    Meier P, Dautheville-Guibal S, Ronco PM, Rossert J. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17: 148-149.PubMedGoogle Scholar
  46. 46.
    Schliefer K, Rockstroh JK, Spengler U, Sauerbruch T. Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet 1997; 350: 413-414.PubMedGoogle Scholar
  47. 47.
    Bienvenu B, Martinez F, Devergie A, Rybojad M, Rivet J, Ballenger P, Morel P, Gluckman E, Lebbe C. Topical use of cidofovir induced acute renal failure. Transplantation 2002; 73: 661-662.PubMedGoogle Scholar
  48. 48.
    Szczepanska-Konkel M, Yusufi ANK, VanScoy M, Webster SK, Dousa TP. Phosphonocarboxylic acids as specific inhibitors of Na+-dependent transport of phosphate across renal brush border membrane. J Biol Chem 1986; 261: 6375-6383.PubMedGoogle Scholar
  49. 49.
    Yusufi ANK, Szczepanska-Konkel M, Kempson SA, McAteer JA, Dousa TP. Inhibition of human renal epithelial Na+/Pi cotransport by phosphono formic acid. Biochem Biophys Res Comm 1986; 139: 679-686.PubMedGoogle Scholar
  50. 50.
    VanScoy M, Loghman-Adham M, Onsgard M, Szcepanska-Konkel M, Homma S, Knox FG, Dousa TP. Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo. Am J Physiol 1988; 255: F984-F994.PubMedGoogle Scholar
  51. 51.
    Ringden O, Lonnqvist B, Paulin T, Ahlmen J, Klintmalm G, Wahren B, Lernestedt J-O. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986; 17: 373-387.PubMedGoogle Scholar
  52. 52.
    Jacobson MA, O’Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syn drome. Antimicrob Agents Chemother 1989; 33: 736-741.PubMedGoogle Scholar
  53. 53.
    Cacoub P, Deray G, Baumelou A, Le Hoang P, Rozenbaum W, Gentilini M, Soubrie C, Rousselie E, Jacobs C. Acute renal failure induced by foscar net: 4 cases. Clin Nephrol 1988; 29: 315-318.PubMedGoogle Scholar
  54. 54.
    Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, Rozenheim M, Baumelou A, Dohin E, Gentilini M, Jacobs C. Foscarnet nephrotoxicity: mechanism, incidence, and prevention. Am J Nephrol 1989; 9: 316-321.PubMedGoogle Scholar
  55. 55.
    Jacobson MA. Review of the toxicities of foscarnet. J AIDS 1992; 5(Suppl 1): S11-S17.Google Scholar
  56. 56.
    Chatelain E, Deminiere C, Lacut JY, Potaux L. Severe renal failure and polyneuritis induced by foscarnet. Nephrol Dial Transplant 1998; 13: 2368-2369.PubMedGoogle Scholar
  57. 57.
    Deray G, Cacoub P, Le Hoang P, Baumelou A, Soubrie C, Rousselie F, Morer I, Jacobs C. Foscarnet-induced acute renal failure and effective ness of haemodialysis. Lancet 1987; 2: 216.PubMedGoogle Scholar
  58. 58.
    Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxocity. Ann Intern Med 1990; 113: 332.PubMedGoogle Scholar
  59. 59.
    Beaufils H, Deray G, Katlama C, Dohin E, Henin D, Sazdovitch V, Jouanneau C. Foscarnet and crystals in glomerular capillary lumens. Lancet 1990; 336: 755.PubMedGoogle Scholar
  60. 60.
    Nyberg G, Svalander C, Blohme I, Persson H. Tubulointerstitial nephritis caused by the antiviral agent foscarnet. Transplant Int 1989; 2: 223-227.Google Scholar
  61. 61.
    Zanetta G, Maurice-Estepa L, Mousson C, Justrabo E, Daudon M, Rifle G, Tanter Y. Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation. Transplantation 1999; 67: 1376-1378.PubMedGoogle Scholar
  62. 62.
    Trolliet P, Dijoud F, Cotte L, Cahen R, Francois B, Trepo C, Patricot LM. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am J Nephrol 1995; 15: 256-259.PubMedGoogle Scholar
  63. 63.
    Maurice-Estapa L, Daudon M, Katlama C, Jouanneau C, Sazdovitch V, Lacour B, Beaufils H. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kid Dis 1998; 32: 392-400.Google Scholar
  64. 64.
    Justrabo E, Zanetta G, Martin L, Assem M, Mousson C, Maurice-Estepa L, Rifle G, Tanter Y. Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection. Histopathology 1999; 34: 365-369.PubMedGoogle Scholar
  65. 65.
    Goldfarb DS, Coe FL. Foscarnet crystal deposition and renal failure. Am J Kid Dis 1998; 32: 519-520.PubMedGoogle Scholar
  66. 66.
    Farese RV Jr, Schambelan M, Hollander H, Stringari S, Jacobson MA. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovi rus retinitis. Ann Intern Med 1990; 112: 955-956.PubMedGoogle Scholar
  67. 67.
    Conn J, Colman P, Brown G, Street A, Bate K. Nephrogenic diabetes insipidus associated with foscarnet - a case report. J Antimicrob Chemother 1996; 37: 1180-1181.Google Scholar
  68. 68.
    Navarro JP et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis. 1996; 27(3):431-4.PubMedGoogle Scholar
  69. 69.
    Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999; 2: 449-456Google Scholar
  70. 70.
    Hoch, BS, Shahmehdi SJ, Louis BM, Lipner HI. Foscarnet alters antidiuretic hormone-mediated transport. Antimicrob Agents Chemother 1995; 39: 2008-2012.Google Scholar
  71. 71.
    Youle MS, Clarbour J, Gazzard B, Chanas A. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamadine. Lancet 1988; 1: 1455-1456.PubMedGoogle Scholar
  72. 72.
    Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale A. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 1991; 72: 1130-1135.PubMedGoogle Scholar
  73. 73.
    Noormohamed FH, Youle MS, Tang B, Martin-Munley S, Gazzard BG, Lant AF. Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients. Antivir Ther 1996; 1: 172-179.PubMedGoogle Scholar
  74. 74.
    Perrin DD, Stunzi H. Viral chemotherapy: antiviral actions of metal ions and metal-chelating agents. Pharmac Ther 1981; 12: 255-297.Google Scholar
  75. 75.
    Huycke MM, Naguib MT, Stroemmel MM, Blick K, Monti K, Martin-Munley S, Kaufman C. A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegaloviral infection. Antimicrob Agents Chemother 2000; 44: 2143-2148.PubMedGoogle Scholar
  76. 76.
    Omar RF, Dusserre N, Desormeaux A, Poulin L, Tremblay M, Beauchamp D, Bergeron M. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob Agents Chemother 1995; 39: 1973-1978.PubMedGoogle Scholar
  77. 77.
    Katlama C, Tubiana R, Rosenheim M, Valantin MA, Caumes E, Bricaire F, Gentilini M. Dideoxyinosine-associated hypokalaemia. Lancet 1991; 337: 183.PubMedGoogle Scholar
  78. 78.
    Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groop man JE. Phase I study of 2’-3’-dideoxyinosine administered orally twice daily to patients with AIDS and AIDS-related complex and hematologic intolerance to zidovudine. Am J Med 1991; 91: 471-478.PubMedGoogle Scholar
  79. 79.
    Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hart man N, Johns DG, Broder S. Long-term toxicity/activity profile of 2’, 3’-dideoxyi nosine in AIDS or AIDS-related complex. Lancet 1990; 336: 526-529.PubMedGoogle Scholar
  80. 80.
    Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, LcLaren C, Pettinelli C, Valentine FT, Dolin R. 2’, 3’-dideoxyino sine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990; 322: 1333-1340.PubMedGoogle Scholar
  81. 81.
    Richardson D, Liou SH, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS clinical trials group protocols 116A and 116B/117. J AIDS 1993; 6: 1212-1223.Google Scholar
  82. 82.
    Takubo T, Kato T, Kinami J, Hanada K, Ogata H. Effect of lamivudine on uptake of organic cations by rat renal brush-border and basolateral membrane vesicles. J Pharm Pharmacol 2000; 52: 569-575.PubMedGoogle Scholar
  83. 83.
    Krishnan M, Nair R, Haas M, Atta MG. Acute renal failure in an HIV-positive 50- year old man. Am J Kidney Dis 2000; 36: 1075-1078.PubMedGoogle Scholar
  84. 84.
    Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 2000; 295: 10-15.PubMedGoogle Scholar
  85. 85.
    Fisher E, Brosgart C, Cohn D, Chaloner K, Pulling C, Semetter B, Alston B, El-Sadr W, CPCRA 039 Team. Safety of adefovir dipivoxil (ADV ) and incidence of proximal tubular disorders (PRTD) in a placebo-controlled trial in patients with advanced HIV disease. 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999 (abstract 678).Google Scholar
  86. 86.
    Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winlsow D, Toole JJ, Coakley D. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. JAMA 1999; 282: 2305-2312.PubMedGoogle Scholar
  87. 87.
    Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D’agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734-740.PubMedGoogle Scholar
  88. 88.
    Arnaudo E, Dalakas M, Shanske S, Morales CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-510.PubMedGoogle Scholar
  89. 89.
    Chen SC, Barker SM, Mitchell DH, Stevens SM, O’Neill P, Cunningham AL. Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for human immunodeficiency virus (HIV ) infection. Pathology 1992; 24: 109-111.PubMedGoogle Scholar
  90. 90.
    Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322: 1098-1105.PubMedGoogle Scholar
  91. 91.
    Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625-628.PubMedGoogle Scholar
  92. 92.
    Zeviani M, Tiranti V, Plantadosi C. Reviews in molecular medicine. Medicine 1999; 77: 59-72.Google Scholar
  93. 93.
    Johns DR. Mitochondrial DNA and disease. N Engl J Med 1995; 33(10):638-644.Google Scholar
  94. 94.
    Niaudet P, Rotig A. The kidney in mitochondrial cytopathies. Kidney Int 1997; 51: 1000-1007.PubMedGoogle Scholar
  95. 95.
    Sundar K, Suarez M, Banogon PE, Shapiro JM. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997;25: 1425-1430.PubMedGoogle Scholar
  96. 96.
    Gopinath R, Hutcheon M, Cheema-Dhadli S, Halperin M. Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: biochemical studies. J Am Soc Nephrol 1992; 3: 1212-1219.PubMedGoogle Scholar
  97. 97.
    Chattha G, Arieff AI, Cummings C, Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118: 37-39.PubMedGoogle Scholar
  98. 98.
    Haupt MT, Carlson RW, Fulop M, Coyle T, Chariot P, Baram D, Chattha G. Lactic acidosis and AIDS. Ann Intern Med 1993;119: 343345.Google Scholar
  99. 99.
    Shaer A, Rastegar A. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. Am J Nephrol 2000; 20: 332-338.PubMedGoogle Scholar
  100. 100.
    Bleeker-Rovers CP, Kadir SW, vanLeusen R, Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 2000; 57: 190-193.PubMedGoogle Scholar
  101. 101.
    Bartley PB, Westacott L, Boots RJ, Lawson M, Potter JM, Hyland VJ, Woods ML. Large hepatic mitochondrial DNA deletions as-sociated with L-lactic acidosis and highly active antiretroviral therapy. AIDS 2001; 15: 419-420.PubMedGoogle Scholar
  102. 102.
    Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30: 198-200.PubMedGoogle Scholar
  103. 103.
    John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ Mal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.PubMedGoogle Scholar
  104. 104.
    Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192-196.PubMedGoogle Scholar
  105. 105.
    Brinkman K, terHofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-1744.PubMedGoogle Scholar
  106. 106.
    Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911-936.PubMedGoogle Scholar
  107. 107.
    Swartz M. Mitochondrial toxicity - new adverse drug effects. N Engl J Med 1995; 333: 1146-1148.PubMedGoogle Scholar
  108. 108.
    CôtéHCF, Brumme ZL, Craib KJP, Alexander CS, WynhovenB, Ting L, Wong H, Harris M, Harrigan PR, O’Shaughnessy MV, Montaner JSG. Changes in mitochondrial DNA as a marker of nuceloside toxicity in HIV-infected patients. New Engl J Med 2002; 346: 811-820.PubMedGoogle Scholar
  109. 109.
    McKenzie R, Fried M, Sallie R, Conjeevaram H, DiBisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH. Hepatic failure and lactic acidosis due to fialuridine (flau), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-1105.PubMedGoogle Scholar
  110. 110.
    Chariot P, Ruet E, Authier FJ, Levy Y, Gherardi R. Acute rhabdomyolysis in patients infected by human immunodeficiency virus. Neurology 1994; 44: 1692-1696.PubMedGoogle Scholar
  111. 111.
    Foulty B, Frerman F, Reves R. Riboflavin to treat NRTI-induced lactic acidosis. Lancet 1999; 352: 291-292.Google Scholar
  112. 112.
    Luzzati R, DelBravo P, DiPerri G, Luzzani A, Concia E. Riboflavine and severe lactic acidosis. Lancet 1999; 353: 901-902.PubMedGoogle Scholar
  113. 113.
    Claessens YE, Cariou A, Chiche JD, Dauriat G, Dhainaut JF. L-carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 2000; 14: 472-473.PubMedGoogle Scholar
  114. 114.
    Chodock R, Eleftherios M, Shemin D, Valgerdur R, Yodice P, Renzi R, Tashima K, Towe C, Rich J. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis - role of haemodialysis treatment. Nephrol Dial Transplant 1999; 14: 2484-2486.PubMedGoogle Scholar
  115. 115.
    Crowther MA, Callaghan W, Hodsman AB, Mackie ID. Dideoxyinosine-associated nephrotoxicity. AIDS 1993; 7: 131-132.PubMedGoogle Scholar
  116. 116.
    Morris AAM, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS 2001; 15: 140-141.PubMedGoogle Scholar
  117. 117.
    Krishnan M, Nair R, Haas M, Atta MG. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 2000; 36: 1075-1078.PubMedGoogle Scholar
  118. 118.
    Ahmad M. Abacavir -induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006; 52(4): 296-7.PubMedGoogle Scholar
  119. 119.
    Coca S, Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-344.PubMedGoogle Scholar
  120. 120.
    Verhelst D, Monge M, Meynard J-L, Fouqueray B, Mougenot B, Girard P-M, Ronco P, Rossert J. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-1333PubMedGoogle Scholar
  121. 121.
    Malik, A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment - case report and review of the literature. J Infection 2005; 51:e61-65.Google Scholar
  122. 122.
    Murphy MD, O;Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36:1082-5.PubMedGoogle Scholar
  123. 123.
    Rollot F, Nazal EM, Chauvelot-Moachon L et al. Tenofovir-related fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37:e174-6.PubMedGoogle Scholar
  124. 124.
    Cirino CM, Kan VL. Hypokalemia in HIV patients on tenofovir. AIDS 2006; 20(12):1671-1673.PubMedGoogle Scholar
  125. 124a.
    Zimmerman AE, Pizzoferrato T, Bedford J et al. Tenofovir - associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 2006;42:283-90.Google Scholar
  126. 124b.
    Vidal F, Domingo JC, Guallar J. et al. In vitro Cytotoxicity and Mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimic Agents Chemother 2006; 50(11): 3824-3832.Google Scholar
  127. 125.
    Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, Christ DD. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999; 27: 1319-1333.PubMedGoogle Scholar
  128. 126.
    Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT. The species dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 2000; 169: 102-113.PubMedGoogle Scholar
  129. 127.
    Barbour TD. Furlong TJ, Finlayson RJ. Efavirenz-associated podocyte damage. AIDS. 2007; 21(2):257-8.PubMedGoogle Scholar
  130. 128.
    Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med 2002; 112:505.PubMedGoogle Scholar
  131. 129.
    Olyaei AJ, deMattos AM, Bennett WM. Renal toxicity of protease inhibitors. Curr Opin Nephrol Hypertens 2000; 9: 473-476.PubMedGoogle Scholar
  132. 130.
    Balani SK, Woolf EJ, Hoagland VL, Sturgill MG. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1995; 24: 1389-1394.Google Scholar
  133. 131.
    Kopp JB, Miller KD, Mican JM, Feuerstein IM, Vaughan E, Baker C, Pannell LK, Falloon J. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-125.PubMedGoogle Scholar
  134. 132.
    Reiter WJ, Pernerstorfer-Schon H, Dorfinger K, Hofbauer J, Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999; 161: 1082-1084.PubMedGoogle Scholar
  135. 133.
    Gagnon, RF, Tecimer SN, Watters, AK, Tsoukas CM. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kid Dis 2000; 36: 507-515.PubMedGoogle Scholar
  136. 134.
    Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis amount HIV-positive patients. AIDS 1998; 12: 2433-2437.PubMedGoogle Scholar
  137. 135.
    Trainor LD, Steinberg JP, Austin GW, Solomon HM. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Arch Pathol Lab Med 1998; 122: 256-259.PubMedGoogle Scholar
  138. 136.
    Padberg J, Fritsche L, Bergmann F, Schurmann D, Suttorp N. Nephropathy and renal colic in patients treated with indinavir, ritonavir plus indinavir or ritonavir plus saquinavir. AIDS 1999; 13: 2173-2174.PubMedGoogle Scholar
  139. 137.
    Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Furtuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, DiCintio E, Martinelli C, Faggion I, Landonio S, Quirino T. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) group. J AIDS 2000; 23: 236-245.Google Scholar
  140. 138.
    Herman JS, Ives NJ, Nelson M, Gazzard BG, Easterbrook PJ. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001; 48: 355-360.PubMedGoogle Scholar
  141. 139.
    Schwartz, BF, Schenkman N, Armenakas NA, Stoller ML. Imaging characteristics of indinavir calculi. Am J Urol 1999; 161: 10851087.Google Scholar
  142. 140.
    Kohan AD, Armenakas NA, Fracchia JA. Indinavir urolithiasis: an emerging cause of renal colic inpatients with human immunodeficiency virus. J Urol 1999; 161: 1765-1768.PubMedGoogle Scholar
  143. 141.
    Berns JS, Cohen RM, Silverman M, Turner J. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kid Dis 1997; 30: 558-560.PubMedGoogle Scholar
  144. 142.
    Kalaitzis C. Dimitriadis G. Tsatidis T. Kuntz R. Touloupidis S. Kelidis G. Treatment of indinavir sulfate induced urolithiasis in HIVpositive patients. Int Urol Nephrol 2002; 34(1):13-5.PubMedGoogle Scholar
  145. 143.
    Green ST, McKendrick MW, Schmid ML, Mohsen AH, Prakasam SF. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS 1998; 9: 555.PubMedGoogle Scholar
  146. 144.
    Engeler DS, Hubert J, Rentsch KM, Ruef C, Oertle D, Suter S. Nelfinavir urinary stones. J Urol 2002; 167: 1384-1385.PubMedGoogle Scholar
  147. 145.
    Pacanowski J, Poirer JM, Petit I, Meynard JL, Girard PM. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006; 20(16):2131.PubMedGoogle Scholar
  148. 146.
    Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336: 138-139.PubMedGoogle Scholar
  149. 147.
    Sarcletti M, Petter A, Zangerle R. Indinavir and interstitial nephritis. Ann Intern Med 1998; 128: 320-322.PubMedGoogle Scholar
  150. 148.
    Grabe DW, Eisele G, Miller C, Singh J, Stein D. Indinavir-induced nephropathy. Clin Nephrol 1999; 51: 181-183.PubMedGoogle Scholar
  151. 149.
    Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998; 50: 194-196.PubMedGoogle Scholar
  152. 150.
    Jaradat M, Phillips C, Yum MN, Cushing H, Moe S. Acute tubulointerstitial nephritis attributable to indinavir therapy. Am J Kid Dis 2000; 35: 1-5.Google Scholar
  153. 151.
    Marroni M, Gaburri M, Mecozzi F, Baldellli F. Acute interstitial nephritis secondary to the administration of indivavir. Ann Pharmocother 1998; 32: 843-844.Google Scholar
  154. 152.
    Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long term treatement with indinavir. New Engl J Med 1999; 340: 392-393.PubMedGoogle Scholar
  155. 153.
    Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2002; 40:1331-3.Google Scholar
  156. 154.
    Duong M, Sgro C, Grappin M, Biron F, Boibieux A. Renal failure after treatment with ritonavir. Lancet 1996; 348: 693-694.PubMedGoogle Scholar
  157. 155.
    Witzke C, Plentz A, Schafers RF, Reinhardt W, Heemann U, Philipp T. Side effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS 1997; 11: 836-838.PubMedGoogle Scholar
  158. 156.
    Bochet MV, Jacquiaud C, Valantin MA, Katlama C, Deray G. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med 1998; 105: 457.PubMedGoogle Scholar
  159. 157.
    Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med 1997; 336: 138.PubMedGoogle Scholar
  160. 158.
    Lalezari JP, Henry K, O’Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.PubMedGoogle Scholar
  161. 159.
    Ing TS, Daugirdas JT, Soung LS, Klawans HL, Maharker SD, Hayashi JA, Geis WP, Hong JE. Toxic effects of amantadine in patients with renal failure. Can Med Assoc J 1979; 120: 695-698.PubMedGoogle Scholar
  162. 160.
    Ing TS, Rahn AC, Armbruster KFW, Oyama JH, Klawans HL. Amantadine accumulation in renal failure. N Engl J Med 1974; 291: 1257.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jeffrey S. Berns
    • 1
  • Alden Doyle
    • 1
  • Nishaminy Kasbekar
    • 1
  1. 1.Renal-Electrolyte and Hypertension DivisionUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations